Propranolol as treatment of patients with angiosarcoma before their standard therapy.

Phase 1

• Conditions: Angiosarcoma; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2019-002947-41-NL
• Lead Sponsor: etherlands Cancer Institute- Antoni van Leeuwenhoek

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-10-08
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

o Histological proof of angiosarcoma
o Patients with primary, recurrent and metastasised disease are eligible;
o Age of 18 years or more;
o Able and willing to give written informed consent;
o WHO performance status of 0, 1 or 2;
o Evaluable disease according to RECIST 1.1 criteria; radiologic visible disease is not obligated in patients with cutaneous angiosarcoma
o Patients with a window of at least 3 weeks before surgery or systemic therapy;
o At least one tumor lesion accessible to safely biopsy per clinical judgement of the treating physician.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 14
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 14

Exclusion Criteria

o Contraindication for propranolol therapy,
o Current treatment with ß-blockade therapy.
o Any anticancer treatment within 30 days prior to receiving the first dose of investigational treatment; with the exception of hormonal therapy for breast cancer.
o Concurrent treatment with an anticancer therapy: with the exception of hormonal therapy for breast cancer.
opregnancy

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified